CA2593623A1 - Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur - Google Patents

Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur Download PDF

Info

Publication number
CA2593623A1
CA2593623A1 CA002593623A CA2593623A CA2593623A1 CA 2593623 A1 CA2593623 A1 CA 2593623A1 CA 002593623 A CA002593623 A CA 002593623A CA 2593623 A CA2593623 A CA 2593623A CA 2593623 A1 CA2593623 A1 CA 2593623A1
Authority
CA
Canada
Prior art keywords
flavonol
ksbgf
processes
kidney
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002593623A
Other languages
English (en)
Inventor
Mian Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002593623A priority Critical patent/CA2593623A1/fr
Publication of CA2593623A1 publication Critical patent/CA2593623A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002593623A 2007-07-09 2007-07-09 Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur Abandoned CA2593623A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002593623A CA2593623A1 (fr) 2007-07-09 2007-07-09 Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002593623A CA2593623A1 (fr) 2007-07-09 2007-07-09 Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur

Publications (1)

Publication Number Publication Date
CA2593623A1 true CA2593623A1 (fr) 2009-01-09

Family

ID=40224422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002593623A Abandoned CA2593623A1 (fr) 2007-07-09 2007-07-09 Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur

Country Status (1)

Country Link
CA (1) CA2593623A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827220A (zh) * 2012-08-24 2012-12-19 湖州市食品药品检验所 从荷叶中分离芦丁、金丝桃苷、异槲皮苷和槲皮素的方法
CN111920837A (zh) * 2019-09-06 2020-11-13 江苏苏中药业集团股份有限公司 一种黄蜀葵花提取物及其在制备尿路感染药物中的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827220A (zh) * 2012-08-24 2012-12-19 湖州市食品药品检验所 从荷叶中分离芦丁、金丝桃苷、异槲皮苷和槲皮素的方法
CN102827220B (zh) * 2012-08-24 2015-04-15 湖州市食品药品检验所 从荷叶中分离芦丁、金丝桃苷、异槲皮苷和槲皮素的方法
CN111920837A (zh) * 2019-09-06 2020-11-13 江苏苏中药业集团股份有限公司 一种黄蜀葵花提取物及其在制备尿路感染药物中的应用

Similar Documents

Publication Publication Date Title
US20080009451A1 (en) Applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor
CN109071645A (zh) 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
Liu et al. Effects of the combined extracts of Herba Epimedii and Fructus Ligustri Lucidi on bone mineral content and bone turnover in osteoporotic rats
Yang et al. Root bark of Sambucus Williamsii Hance promotes rat femoral fracture healing by the BMP-2/Runx2 signaling pathway
CN102811622A (zh) 用于治疗腱病的血小板衍生生长因子组合物和方法
Choi et al. Promotion of osteogenesis by Sweroside via BMP2‐involved signaling in postmenopausal osteoporosis
Rathi et al. Trigonelline demonstrated ameliorative effects in dexamethasone induced osteoporotic rats
Zhang et al. Anti-inflammatory effects of aucubin in cellular and animal models of rheumatoid arthritis
CA2593623A1 (fr) Applications du facteur de croissance osseuse du aux secretions renales et utilisation pharmaceutique du flavonol et des glycoflavonols pour stimuler la production dudit facteur
CN102395363A (zh) Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物
KR100483496B1 (ko) 봉독 수용성분을 함유하는 소염 및 진통용 조성물
CN1207022C (zh) 促进骨折愈合和骨关节损伤修复的药物组合物及其制备方法和应用
CN105381039B (zh) 一种治疗原发性骨质疏松症的中药组合物及其制备方法
CN105770850A (zh) 一种辅助治疗骨关节疾病的保健品及其制备方法
Arya et al. A18239 Apigenin ameliorates streptozotocin induced diabetic nephropathy in rats by modulation of oxidative stress, apoptosis and inflammation through MAPK pathway
Park et al. Polyherbal formula SC-E3 inhibits rheumatoid arthritis activity in a mouse model of type-II collagen-induced arthritis
CN102686236A (zh) 人变形性膝关节症的预防剂和/或治疗剂和/或恶化抑制剂
Chakuleska et al. Beneficial effects of the fructus Sophorae extract on experimentally induced osteoporosis in New Zealand white rabbits
CN112691167B (zh) 一种治疗抑郁症的中药组合物及其制剂和应用
CN107898785A (zh) 氧化苦参碱在制备抗破骨细胞介导的骨丢失药物中的应用
CN114869869B (zh) Eugenol在预防和/或治疗骨关节炎中的应用
ES2452916T3 (es) Vicenin 2 y derivados del mismo para utilizar como agente antiespasmódico y/o procinético
US20230310342A1 (en) Osteogenic agents and uses thereof
Aydın et al. The effect of royal jelly supplementation for three months on bone markers in postmenopausal osteoporotic women
CN102935079A (zh) 咖啡酸3,4-二羟基苯乙酯的制药用途

Legal Events

Date Code Title Description
FZDE Dead